Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y -2.80%60 Debt-to-Equity is 0.30 as of Dec. 2025, which is 14% below its 10-year median of 0.35. GuruFocus rates FRA:F7Y with a GF Score™ of 60/100 and a GF Value™ of €1.44. The stock has 3 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Gaush Meditech ranks better than 50.79% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Gaush Meditech's Debt-to-Equity or its related term are showing as below:
FRA:F7Y'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.46 Med: 0.35 Max: 42.19
Current: 0.24
During the past 7 years, the highest Debt-to-Equity Ratio of Gaush Meditech was 42.19. The lowest was -1.46. And the median was 0.35.
FRA:F7Y's Debt-to-Equity is ranked better than 50.79% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs FRA:F7Y: 0.24
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Gaush Meditech Debt-to-Equity Related Terms
Gaush Meditech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F7Y vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Gaush Meditech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (FRA:F7Y) has a Debt-to-Equity of 0.30 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gaush Meditech and its competitors. This is 14% below median its historical median of 0.35. According to the industry distribution chart, Gaush Meditech ranks #344 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 49.2%.
Is Gaush Meditech's Debt-to-Equity too high?
Gaush Meditech's current Debt-to-Equity of 0.30 is 14% below median its 10-year median of 0.35. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Gaush Meditech's value of 0.30 is 25% above this industry median. Based on the distribution chart, Gaush Meditech ranks #344 out of 699 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gaush Meditech has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #344 out of 699 companies for Debt-to-Equity. This puts Gaush Meditech in the upper half of its industry. The industry median Debt-to-Equity is 0.24. Gaush Meditech's value of 0.30 is 25% above this benchmark. While the company's 10-year median is 0.35 vs. the industry median of 0.24, Gaush Meditech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current Debt-to-Equity of 0.30 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current Debt-to-Equity is 0.30, which is 14% below median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Gaush Meditech (FRA:F7Y) has a current Debt-to-Equity of 0.30. The stock's GF Value™ is €1.44, compared to a current price of €0.49 — trading 66.3% below its estimated fair value. The current Debt-to-Equity is 0.30, which is 14% below median its 10-year median of 0.35 and 25% above the Medical Devices & Instruments industry median of 0.24. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current Debt-to-Equity is 0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.49 is trading 66.3% below its estimated GF Value™ of €1.44.
Key valuation signals for FRA:F7Y:
Debt-to-Equity: 0.30 (14% below median its 10-year median of 0.35)
GF Value™: €1.44 vs. price of €0.49 (66.3% below fair value)
Industry Position: 25% above the Medical Devices & Instruments median (#344 of 699)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score
Get the complete analysis for FRA:F7Y
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
